Mendoza Bergmann (formatcod2)

The on-going data-science and Artificial Intelligence (AI) revolution offer researchers a fresh set of tools to approach structure-based drug design problems in the computer-aided drug design space. A novel programmatic tool that incorporates in silico and deep learning based approaches for de novo drug design for any target of interest has been reported. Once the user specifies the target of interest in the form of a representative amino acid sequence or corresponding nucleotide sequence, the programmatic workflow of the tool generates compounds from the PubChem ligand library and novel SMILES of compounds not present in any ligand library but are likely to be active against the target. Following this, the tool performs a computationally efficient In-Silico modeling of the target and the newly generated compounds and stores the results of the protein-ligand interaction in the working folder of the user. Further, for the protein-ligand complex associated with the best protein-ligand interaction, the tool performs an automated Molecular Dynamics (MD) protocol and generates plots such as RMSD (Root Mean Square Deviation) which reveal the stability of the complex. A demonstrated use of the tool has been shown with the target signatures of Tumor Necrosis Factor-Alpha, an important therapeutic target in the case of anti-inflammatory treatment. The future scope of the tool involves, running the tool on a High-Performance Cluster for all known target signatures to generate data that will be useful to drive AI and Big data driven drug discovery. The code is hosted, maintained, and supported at the GitHub repository given in the link below https//github.com/bengeof/Target2DeNovoDrugCommunicated by Ramaswamy H. Sarma.Leucine can promote slow-twitch muscle fibers formation, and this effect may be mediated by AMPK signaling pathway. In addition, adiponectin (AdipoQ) plays an important role in regulation of muscle fiber type transformation. AdipoQ is located in the upstream of AMPK and its secretion can be regulated by leucine. Therefore, the aim of this study was to explore whether leucine affects muscle fiber type transformation through AdipoQ signaling pathway. Our data showed that 4 mM leucine significantly increased protein expression levels of slow MyHC, Myoglobin, Troponin I-SS, AdipoQ, AdipoR1, phospho-AMPK (p-AMPK) and PGC-1α and mRNA expression levels of AMPKα2, PGC-1α, AdipoQ and AdipoR1, and significantly decreased fast MyHC protein expression. PX-478 manufacturer In addition, 4 mM leucine significantly increased the SDH activity while significantly decreased the LDH activity. However, knockdown of AdipoR1 expression by AdipoR1-siRNA abolished leucine-induced upregulation of protein expressions of slow MyHC, AdipoR1, p-AMPK, PGC-1α and NRF1, mRNA expressions of MyHC I, MyHC IIa, AdipoR1, AMPKα2 and PGC-1α, ATP5G, TFAM and NRF1, and mtDNA level, as well as downregulation of protein expression of fast MyHC and mRNA expression of MyHC IIb. Together, our data revealed that leucine promotes muscle fiber type transformation from fast-twitch to slow-twitch through AdipoQ signaling pathway.Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized